iX Biopharma (SGX:42C) disclosed the results from its SEISMIC-CBD study on a new cannabidiol (CBD) sublingual wafer, according to a Monday filing with the Singapore Exchange.
The study evaluated the wafer's safety and efficacy in patients with kidney failure.
The trial involved 12 patients with advanced kidney disease, including those undergoing dialysis. Over six weeks, the CBD wafer was found to be generally safe and well-tolerated, with no serious adverse events reported.
Improvements were observed in several symptoms, including sleep quality, restless legs syndrome, pain, anxiety, and anorexia.
Of the seven patients who completed the full treatment, three reported significant symptom relief. Side effects noted included nausea, dizziness, and drowsiness.
Four patients chose to continue using the wafer post-study, though one patient did pass away due to kidney disease.
The study suggests that CBD, which is metabolized primarily in the liver, may not be significantly affected by impaired kidney function, the filing said. This supports the need for larger, controlled trials.
The pharmaceutical company's shares were up more than 4% in recent Tuesday trade.
Price (SGD): S$0.03, Change: S$+0.001, Percent Change: +4.17%
Comments